Overview

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Status:
Not yet recruiting

Trial end date:
2024-11-27

Target enrollment:

Participant gender:

Summary

A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who have Failed or are Intolerant to Bacillus Calmette-Guerin (BCG) Vaccine

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

LintonPharm Co.,Ltd.

Treatments:

Catumaxomab